531 related articles for article (PubMed ID: 18281781)
1. [Future directions of anticancer drug development in Japan].
Akaza H; Kawai K; Tsuruo T; Tsukagoshi S; Aiba K; Shimada Y; Kakeji Y; Ishikawa H; Ikeda T; Nakamura S; Tamura T; Yamamoto N; Isonishi S; Hinotsu S; Hirose M; Katsura J
Gan To Kagaku Ryoho; 2008 Feb; 35(2):351-60. PubMed ID: 18281781
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
4. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
Engel J; Emons G; Pinski J; Schally AV
Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. [The history of developing anticancer Drugs and their evaluation guidelines in Japan].
Maeda H; Kurokawa T
Yakushigaku Zasshi; 2014; 49(2):196-204. PubMed ID: 25799841
[TBL] [Abstract][Full Text] [Related]
7. Current status of chemotherapy for advanced colorectal cancer in Japan.
Yamada Y
Clin Colorectal Cancer; 2008 Jan; 7(1):15-24. PubMed ID: 18279573
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
Ekimoto H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
[TBL] [Abstract][Full Text] [Related]
10. Current status and problems in development of molecular target agents for gastrointestinal malignancy in Japan.
Boku N
Jpn J Clin Oncol; 2010 Mar; 40(3):183-7. PubMed ID: 20047861
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy.
Shibata S; Matsushita M; Saito Y; Suzuki T
Ther Innov Regul Sci; 2018 Nov; 52(6):718-723. PubMed ID: 29714569
[TBL] [Abstract][Full Text] [Related]
12. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
13. [Current problems of early phase clinical trials for new anticancer agents in Japan].
Nakagawa K; Fukuoka M
Gan To Kagaku Ryoho; 2000 Jun; 27(6):925-9. PubMed ID: 10897223
[TBL] [Abstract][Full Text] [Related]
14. [Aiming for zero blindness].
Nakazawa T
Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
[TBL] [Abstract][Full Text] [Related]
15. Satraplatin: BMS 182751, BMY 45594, JM 216.
Drugs R D; 2007; 8(2):125-32. PubMed ID: 17324011
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
17. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
Kawabata-Shoda E; Masuda S; Kimura H
J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
[TBL] [Abstract][Full Text] [Related]
19. [Globalization of clinical trials].
Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
[TBL] [Abstract][Full Text] [Related]
20. Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.
Drugs R D; 2004; 5(4):220-6. PubMed ID: 15230629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
